NEW YORK, NY / ACCESSWIRE / August 16, 2017 / U.S. markets swung between gains and losses on Tuesday as disappointing earnings from major retailers were offset by positive U.S. retail sales data. The Dow Jones Industrial Average eked out a gain of 0.02 percent to close at 21,998.99, its third consecutive daily gain, while the S&P 500 Index declined 0.05 percent to close at 2,464.61. The NASDAQ Composite Index declined 0.11 percent to close at 6,333.01.

"The retail sales numbers that came out today - that's nothing but good news. We had a positive surprise for this month and upward revisions for the past two months," said Brad McMillan, chief investment officer for Commonwealth Financial Network in Waltham, Massachusetts. "People are spending but they're not spending on the same things. So from an economic perspective, it's all good news. From a company-level perspective, there are winners and there are losers."

RDI Initiates Coverage on:

Exelixis, Inc.
https://ub.rdinvesting.com/news/?ticker=EXEL

Sarepta Therapeutics Inc.
https://ub.rdinvesting.com/news/?ticker=SRPT

Exelixis Inc.'s stock edged 0.64% higher Tuesday, to close the day at $26.91. The stock recorded a trading volume of 2,536,754 shares, which was below its three months average volume of 4,227,470 shares. In the last year Exelixis Inc.'s shares have traded in a range of 10.04 - 28.45. The share price has gained 168.03% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $26.26 is greater than its 200-day moving average of $22.46. Shares of Exelixis Inc. are trading at a Price to Earnings ratio of 135.91. Shares of Exelixis have gained approximately 80.48 percent year-to-date.

Access RDI's Exelixis, Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=EXEL

On Tuesday, shares in Sarepta Therapeutics Inc. recorded a trading volume of 1,839,633 shares, which was below the three months average volume of 2,316,710 shares. The stock ended the day 2.93% lower at 36.71. The share price has gained 51.01% from its 52 week low with a 52 week trading range of 24.31 - 63.73.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $37.16 is greater than its 200-day moving average of $32.96. Shares of Sarepta Therapeutics have fallen approximately 33.83 percent year-to-date.

Access RDI's Sarepta Therapeutics Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=SRPT

Our Actionable Research on Exelixis Inc. (NASDAQ: EXEL) and Sarepta Therapeutics Inc. (NASDAQ: SRPT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com